Author Topic: GUD.V - Knight Therapeutics  (Read 60902 times)

snowball82

  • Sr. Member
  • ****
  • Posts: 470


Xerxes

  • Sr. Member
  • ****
  • Posts: 456
Re: GUD.V - Knight Therapeutics
« Reply #171 on: September 21, 2020, 08:10:36 PM »
Who is the funds with quartile 1 return now owning more than 10 % ? Surprise 😉

« The Fund held 13,644,000 common shares of Knight at the end of August, representing approximately 10.42% of all outstanding common shares »


Snowball
For the uninitiated, can you tell us who ?

snowball82

  • Sr. Member
  • ****
  • Posts: 470
Re: GUD.V - Knight Therapeutics
« Reply #172 on: September 22, 2020, 02:55:06 AM »
Who is the funds with quartile 1 return now owning more than 10 % ? Surprise 😉

« The Fund held 13,644,000 common shares of Knight at the end of August, representing approximately 10.42% of all outstanding common shares »


Snowball
For the uninitiated, can you tell us who ?

Resolute funds

snowball82

  • Sr. Member
  • ****
  • Posts: 470
Re: GUD.V - Knight Therapeutics
« Reply #173 on: September 24, 2020, 02:42:22 PM »
Globe says Knight Therapeutics down but not out


2020-09-22 08:36 ET - In the News

The Globe and Mail reports in its Tuesday edition that trading patterns in the run-up toward a vaccine suggest that value stocks (such as those in health care), which have lower growth and tend to be ignored by investors, could perform better. The Globe's David Berman writes that Goldman Sach's analyst David Kostin says, "Many of today's value stocks have faced particularly acute challenges from COVID-19 and will experience the sharpest rebounds in earnings expectations once investors have confidence in the path to normalization." Knight Therapeutics, the Montreal-based pharmaceutical firm, recently completed its acquisition of Brazil's Biotoscana Investments SA -- but COVID-19 stands as a potential obstacle to integration, says McElvaine Investment Management president Tim McElvaine. The stock is down 22 per cent year to date. Mr. McElvaine adds, "So in an environment where COVID is less of a threat, I think that would be helpful to their business." His firm holds a position in Knight. The problem with any value investing strategy, unfortunately, is that value stocks have been lagging the performance of growth stocks for years, frustrating investors who have turned to cheap stocks, notes Mr. Berman.

snowball82

  • Sr. Member
  • ****
  • Posts: 470


snowball82

  • Sr. Member
  • ****
  • Posts: 470
Re: GUD.V - Knight Therapeutics
« Reply #176 on: October 26, 2020, 07:44:43 PM »
The management has a view to have a solid foundation before growth. We know some investors would see 2-3 acquisitions per year and be aggressive like Valeant but it is not their way to execute.

https://www.globenewswire.com/news-release/2020/10/26/2114172/0/en/Knight-Signs-New-Exclusive-AmBisome-Agreement-with-Gilead-in-Brazil.html
« Last Edit: October 26, 2020, 08:29:46 PM by snowball82 »

snowball82

  • Sr. Member
  • ****
  • Posts: 470
Re: GUD.V - Knight Therapeutics
« Reply #177 on: November 07, 2020, 06:10:25 AM »
Someone has forecast or expectations for this quarter ? It should be interesting to know more about Grupo Biotoscana consolidation.

https://www.gud-knight.com/investors-overview/events-webcasts/

snowball82

  • Sr. Member
  • ****
  • Posts: 470
Re: GUD.V - Knight Therapeutics
« Reply #178 on: November 13, 2020, 06:13:04 AM »
Q3 2020 Highlights

Financials

Revenues were $45,239, an increase of $41,209 or 1,023% over prior year.
Gross margin was $19,533 or 43% compared to $3,301 or 82% in prior year.
Interest income generated of $3,188 a decrease of $2,870 or 47% over prior year.
Adjusted earnings1 of $6,582, an increase of $1,020 or 18% over prior year.
Net income for the period was $17,492 compared to a net loss of $2,959 in prior year.
Corporate Developments

Launched a normal course issuer bid (“NCIB”) in July 2020 and purchased 797,952 common shares for an aggregate cost of $4,745.
Completed the tender offer process and acquired all of the outstanding Brazilian Depositary Receipts (“BDR”) of Biotoscana Investments S.A. (“GBT”).
Products

Obtained regulatory approval for Lenvima® and Halaven® in Ecuador.
Received regulatory approval from Health Canada for Imvexxy™ and Bijuva®.
Submitted a supplement to a New Drug Submission (“NDS”) of Nerlynx for HER2-positive metastatic breast cancer.


https://financialpost.com/pmn/press-releases-pmn/globe-newswire-releases/knight-therapeutics-reports-third-quarter-2020-results

no_free_lunch

  • Hero Member
  • *****
  • Posts: 1813
Re: GUD.V - Knight Therapeutics
« Reply #179 on: November 13, 2020, 08:37:35 AM »
I wish they broke out GBT's results.  Do you have a sense of where it's fcf is this quarter and how it performed relative to last quarter?  Is the adjusted earnings effectively GBT fcf minus knight corporate expenses?